The PPMI protocol has recently been amended to add a new cohort of subjects who have been screened for eligibility as PD subjects but have Scans Without Evidence of Dopaminergic Deficit (SWEDD).
Dopamine transporter imaging showing reduction in DAT striatal binding ratio is a key inclusion criteria for PD subjects in PPMI. Approximately 15% of the those subjects screened for PD eligibility in PPMI have not had imaging evidence of dopaminergic deficit and so far have been excluded from further participation in PPMI.
Recently, an ancillary studies proposal was submitted by Danna Jennings, PPMI Site Investigator at the Institute for Neurodegenerative Disorders, to follow those subjects with SWEDD for 2 years through PPMI. The goal of this project is to assess the clinical and biomarker longitudinal changes in subjects with SWEDD and to compare these clinical and biomarker longitudinal changes to PD subjects with abnormal DAT imaging and healthy controls. The study has been accepted and is currently being incorporated into study consent forms and submitted to site IRBs.
The SWEDD cohort will be assessed for 24 months and will follow a similar schedule of events as PPMI PD subjects.
The PPMI protocol has now been amended to include this cohort. Click here to view the new protocol.